Literature DB >> 16894562

Raf kinases: oncogenesis and drug discovery.

Ralf Schreck1, Ulf R Rapp.   

Abstract

Raf kinase signaling has been thoroughly investigated over the last 20 years. A-Raf, B-Raf and C-Raf, the 3 mammalian members of the Raf family, are involved in a variety of cellular processes such as growth, proliferation, survival, differentiation and transformation. The detection of B-RAF mutations in a wide variety of human cancers, the description of wildtype and mutant B-RAF as tumor antigens in melanoma and the promising outcome of clinical trials evaluating the Raf inhibitor Nexavar (Sorafenib, BAY 43-9006) have sparked a broad interest in the scientific community. After a short historical detour and an introduction into Raf kinase signaling, we are going to discuss here recent outcomes of Raf kinase research with respect to tumor formation and give an overview on current efforts to develop anticancer therapies interfering with aberrant Raf kinase signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16894562     DOI: 10.1002/ijc.22144

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  35 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

3.  Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf.

Authors:  Michael Fisher; Mikhail Abramov; Arthur Van Aerschot; Jef Rozenski; Vidula Dixit; Rudy L Juliano; Piet Herdewijn
Journal:  Eur J Pharmacol       Date:  2009-01-30       Impact factor: 4.432

4.  Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.

Authors:  Ying C Henderson; Soon-Hyun Ahn; Ya'an Kang; Gary L Clayman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

5.  Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase.

Authors:  Angela Baljuls; Regina Mahr; Inge Schwarzenau; Thomas Müller; Lisa Polzien; Mirko Hekman; Ulf R Rapp
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

Review 6.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

7.  Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.

Authors:  Xiufeng Pang; Tingfang Yi; Zhengfang Yi; Sung Gook Cho; Weijing Qu; Decha Pinkaew; Ken Fujise; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

8.  Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.

Authors:  Bin Zheng; Joseph H Jeong; John M Asara; Yuan-Ying Yuan; Scott R Granter; Lynda Chin; Lewis C Cantley
Journal:  Mol Cell       Date:  2009-01-30       Impact factor: 17.970

9.  Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

Authors:  Bijay S Jaiswal; Vasantharajan Janakiraman; Noelyn M Kljavin; Jeffrey Eastham-Anderson; James E Cupp; Yuxin Liang; David P Davis; Klaus P Hoeflich; Somasekar Seshagiri
Journal:  PLoS One       Date:  2009-05-27       Impact factor: 3.240

10.  The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

Authors:  Abel D Jarell; Donald Lawrence; Hensin Tsao
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.